StockData
Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc. (TNGX) income statement

TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30126% above fair value
$21.89−0.22 (-1.00%)

Close on Nov 18, 2026Market cap $3.69BP/E –Yield –

Tango Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-253.4%
Net margin
-229.9%
Return on equity, FY2025
-37.2%

Financial strength

Current ratio
50.82
Debt to equity
–
Debt to assets
–
Cash to current liabilities
1702.3%

Valuation

P/E ratio
–
Price to sales
68.59
Price to book
3.60
Dividend yield
–

See a number that looks wrong?